Updating results

PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) (DG23)

Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia

Diagnostics guidance Published May 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...

Technology appraisal guidance Published April 2016

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

Technology appraisal guidance Published April 2016

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Technology appraisal guidance Published March 2016

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease (MTG28)

Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in patients with sickle cell disease

Medical technologies guidance Published March 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Technology appraisal guidance Published February 2016

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

Evidence-based recommendations on therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease

Diagnostics guidance Published February 2016

Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21)

Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems for type 1 diabetes

Diagnostics guidance Published February 2016

Tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay) (DG20)

Evidence-based recommendations on the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for identifying bloodstream bacteria and fungi

Diagnostics guidance Published February 2016

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

This guidance has been updated and replaced by NICE technology appraisal guidance 412.

Technology appraisal guidance Published January 2016

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

Evidence-based recommendations on olaparib (Lynparza)

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Apremilast for treating active psoriatic arthritis (TA372)

This guidance has been updated and replaced by NICE technology appraisal guidance 433.

Technology appraisal guidance Published December 2015

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears

Technology appraisal guidance Published December 2015

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published December 2015

Apremilast for treating moderate to severe plaque psoriasis (TA368)

Technology appraisal guidance Published November 2015

Daclatasvir for treating chronic hepatitis C (TA364)

This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

Technology appraisal guidance Published November 2015

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Technology appraisal guidance Published November 2015

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015

Vortioxetine for treating major depressive episodes (TA367)

Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults

Technology appraisal guidance Published November 2015

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

Diagnostics guidance Published November 2015

Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

Technology appraisal guidance Published October 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults

Technology appraisal guidance Published October 2015

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)

Technology appraisal guidance Published October 2015

Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (AVIDA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive..

Diagnostics guidance Published October 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015

Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C

Medical technologies guidance Published September 2015

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

Technology appraisal guidance Published September 2015

UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)

Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (BHP)

Medical technologies guidance Published September 2015

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

Technology appraisal guidance Published August 2015

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...

Technology appraisal guidance Published August 2015

Guidance on the use of patient-education models for diabetes (TA60)

This guidance has been replaced by NICE guideline NG17.

Technology appraisal guidance Published April 2003 Last updated August 2015

Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

This guidance has been replaced by NICE guideline NG17.

Technology appraisal guidance Published December 2002 Last updated August 2015

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…

Technology appraisal guidance Published July 2015

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

Technology appraisal guidance Published July 2015